{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:15:18Z","timestamp":1791915318113,"version":"4.3.4"},"reference-count":83,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The association between cancer and thrombosis has been known for over a century and a half. However, the mechanisms that underlie this correlation are not fully characterized. Hypercoagulability in cancer patients can be classified into two main categories: Type I and Type II. Type I occurs when the balance of endogenous heparin production and degradation is disturbed, with increased degradation of endogenous heparin by tumor-secreted heparanase. Type II hypercoagulability includes all the other etiologies, with factors related to the patient, the tumor, and\/or the treatment. Patients with poor performance status are at higher risk of venous thromboembolism (VTE). Tumors can result in VTE through direct pressure on blood vessels, resulting in stasis. Several medications for cancer are correlated with a high risk of thrombosis. These include hormonal therapy (e.g., tamoxifen), chemotherapy (e.g., cisplatin, thalidomide and asparaginase), molecular targeted therapy (e.g., lenvatinib, osimertinib), and anti-angiogenesis monoclonal antibodies (e.g., bevacizumab and ramucirumab).<\/jats:p>","DOI":"10.3390\/cancers12030566","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T07:35:30Z","timestamp":1583134530000},"page":"566","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Potential Mechanisms of Cancer-Related Hypercoagulability"],"prefix":"10.3390","volume":"12","author":[{"given":"Nicola J.","family":"Nasser","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-2959","authenticated-orcid":false,"given":"Abed","family":"Agbarya","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Bnai Zion Medical Center, Haifa 31048, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"ref_1","unstructured":"Trousseau, A. (1872). Phlegmasia alba dolens in: Lectures on Clinical Medicine, delivered at the H\u00f4tel-Dieu, Paris, New Sydenham Society."},{"key":"ref_2","first-page":"166","article-title":"Venous thrombosis: On the history of Virchow\u2019s triad","volume":"81","author":"Dickson","year":"2004","journal-title":"Univ. Tor. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1538-7836.2006.01792.x","article-title":"Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin","volume":"4","author":"Nasser","year":"2006","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CAD.0000000000000176","article-title":"Pharmacokinetics of low molecular weight heparin in patients with malignant tumors","volume":"26","author":"Nasser","year":"2015","journal-title":"Anti-Cancer Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1111\/j.1538-7836.2006.02212.x","article-title":"Heparanase induces tissue factor expression in vascular endothelial and cancer cells","volume":"4","author":"Nadir","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0037-1608919","article-title":"Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells","volume":"99","author":"Nadir","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00047.2009","article-title":"Effects of disturbed flow on vascular endothelium: Pathophysiological basis and clinical perspectives","volume":"91","author":"Chiu","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004424-198101000-00013","article-title":"Ultrasonography of blood during stasis and coagulation","volume":"16","author":"Sigel","year":"1981","journal-title":"Investig. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-2007-1004372","article-title":"A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions","volume":"11","author":"Fareed","year":"1985","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): A prospective longitudinal observational study","volume":"6","author":"White","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/bjc.2014.3","article-title":"Thrombosis in ovarian cancer: A case control study","volume":"110","author":"Metcalf","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jcu.20691","article-title":"Asymptomatic deep vein thrombosis in advanced cancer patients: The value of venous sonography","volume":"38","author":"Kuzmin","year":"2010","journal-title":"J. Clin. Ultrasound JCU"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.wneu.2017.12.139","article-title":"High Incidence of Deep Vein Thrombosis in the Perioperative Period of Neurosurgical Patients","volume":"112","author":"Natsumeda","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1179\/1743132812Y.0000000126","article-title":"Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors","volume":"35","author":"Chaichana","year":"2013","journal-title":"Neurol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00595-017-1617-4","article-title":"Risk and incidence of perioperative deep vein thrombosis in patients undergoing gastric cancer surgery","volume":"48","author":"Osaki","year":"2018","journal-title":"Surg. Today"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor\u2013Positive Tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","article-title":"Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer","volume":"89","author":"Fisher","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with Cisplatin: A systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.2008.19.4274","article-title":"Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: A report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group","volume":"27","author":"Starling","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: Mechanisms of action-similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin. Hematol."},{"key":"ref_23","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12010-015-1917-3","article-title":"A comprehensive review on L-asparaginase and its applications","volume":"178","author":"Batool","year":"2016","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1992.tb00032.x","article-title":"Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: A retrospective study","volume":"49","author":"Gugliotta","year":"1992","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2010.08132.x","article-title":"Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe","volume":"149","author":"Qureshi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0049-3848(01)00286-9","article-title":"Thrombotic events revisited in children with acute lymphoblastic leukemia: Impact of concomitant Escherichia coli asparaginase\/prednisone administration","volume":"103","author":"Heinecke","year":"2001","journal-title":"Thromb. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/bjc.2013.374","article-title":"Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer","volume":"109","author":"Nishio","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR Inhibitor\u2013Resistant Non\u2013Small-Cell Lung Cancer","volume":"372","author":"Yang","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_33","first-page":"25","article-title":"Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report","volume":"20","author":"Shiroyama","year":"2016","journal-title":"Respir. Med. Case Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fon.10.75","article-title":"Ramucirumab (IMC-1121B): A novel attack on angiogenesis","volume":"6","author":"Spratlin","year":"2010","journal-title":"Future Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2141.2008.07119.x","article-title":"The story of the discovery of heparin and warfarin","volume":"141","author":"Wardrop","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/ajplegacy.1925.71.3.553","article-title":"The purification of heparin and its presence in blood","volume":"71","author":"Howell","year":"1925","journal-title":"Am. J. Physiol. Leg. Content"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-2318(01)57017-1","article-title":"Structure and biological interactions of heparin and heparan sulfate","volume":"Volume 57","author":"Casu","year":"2001","journal-title":"Advances in Carbohydrate Chemistry and Biochemistry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrm1681","article-title":"Heparan sulphate proteoglycans: The sweet side of development","volume":"6","author":"Hacker","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1039\/C7OB01058C","article-title":"Targeting heparin and heparan sulfate protein interactions","volume":"15","author":"Weiss","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_44","first-page":"30","article-title":"Making heparin safe","volume":"94","author":"Tremblay","year":"2016","journal-title":"Chem. Eng. News"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kouta, A., Jeske, W., Hoppensteadt, D., Iqbal, O., Yao, Y., and Fareed, J. (2019). Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins. Clin. Appl. Thromb. Hemost. Off. J. Int. Acad., 25.","DOI":"10.1177\/1076029619889406"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)","volume":"22","author":"Kakkar","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E","article-title":"Subcutaneous heparin treatment increases survival in small cell lung cancer","volume":"74","author":"Lebeau","year":"1994","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1538-7836.2007.02427.x","article-title":"The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials","volume":"5","author":"Goss","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18167","DOI":"10.1074\/jbc.M801327200","article-title":"Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment","volume":"283","author":"Atzmon","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(03)01478-5","article-title":"Heterodimer formation is essential for heparanase enzymatic activity","volume":"308","author":"Miao","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1074\/jbc.M413370200","article-title":"Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase","volume":"280","author":"Aingorn","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1007\/s00018-008-7584-6","article-title":"Heparanase involvement in physiology and disease","volume":"65","author":"Nasser","year":"2008","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1073\/pnas.0812846106","article-title":"Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis","volume":"106","author":"Nasser","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1042\/bj3301341","article-title":"Human platelet heparanase: Purification, characterization and catalytic activity","volume":"330","author":"Freeman","year":"1998","journal-title":"Biochem. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-2007-1003524","article-title":"Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix","volume":"13","author":"Eldor","year":"1987","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/glycob\/cwy011","article-title":"Overexpression of heparanase in mice promoted megakaryopoiesis","volume":"28","author":"Tan","year":"2018","journal-title":"Glycobiology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"39486","DOI":"10.18632\/oncotarget.8960","article-title":"Heparanase expression upregulates platelet adhesion activity and thrombogenicity","volume":"7","author":"Cui","year":"2016","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/molehr\/2.9.679","article-title":"Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts","volume":"2","author":"Goshen","year":"1996","journal-title":"Mol. Hum. Reprod."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/10518","article-title":"Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis","volume":"5","author":"Vlodavsky","year":"1999","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/molehr\/8.6.566","article-title":"Localization of heparanase in normal and pathological human placenta","volume":"8","author":"Friedmann","year":"2002","journal-title":"Mol. Hum. Reprod."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.placenta.2019.07.004","article-title":"Heparanase regulation of sFLT-1 release in trophoblasts in vitro","volume":"85","author":"Eddy","year":"2019","journal-title":"Placenta"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.placenta.2017.06.006","article-title":"Bovine placentomal heparanase and syndecan expression is related to placental maturation","volume":"57","author":"Hambruch","year":"2017","journal-title":"Placenta"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.blre.2014.10.003","article-title":"Platelet secretion: From haemostasis to wound healing and beyond","volume":"29","author":"Golebiewska","year":"2015","journal-title":"Blood Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbrc.2006.12.189","article-title":"Cloning, expression, and characterization of an alternatively spliced variant of human heparanase","volume":"354","author":"Nasser","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15161","DOI":"10.1073\/pnas.0507279102","article-title":"Adaptive evolution of heparanase in hypoxia-tolerant Spalax: Gene cloning and identification of a unique splice variant","volume":"102","author":"Nasser","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/1872213X11307020007","article-title":"Heparanase patents: Dim past and bright future","volume":"7","author":"Nasser","year":"2013","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1074\/jbc.M802196200","article-title":"Molecular structure of heparan sulfate from Spalax. Implications of heparanase and hypoxia","volume":"284","author":"Sandwall","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tibs.2017.10.007","article-title":"Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression","volume":"43","author":"Vlodavsky","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"ref_70","first-page":"4655","article-title":"Heparanase expression in primary and metastatic pancreatic cancer","volume":"61","author":"Koliopanos","year":"2001","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1091-255X(01)00087-7","article-title":"Human heparanase-1 gene expression in pancreatic adenocarcinoma","volume":"6","author":"Kim","year":"2002","journal-title":"J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract"},{"key":"ref_72","first-page":"864","article-title":"Heparanase expression correlates with angiogenesis and lymphangiogenesis in human lung cancer","volume":"12","author":"Zhang","year":"2009","journal-title":"Zhongguo Fei Ai Za Zhi Chin. J. Lung Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.23680","article-title":"Heparanase is overexpressed in lung cancer and correlates inversely with patient survival","volume":"113","author":"Cohen","year":"2008","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.7314\/APJCP.2015.16.18.8653","article-title":"Heparanase mRNA and Protein Expression Correlates with Clinicopathologic Features of Gastric Cancer Patients: A Meta- analysis","volume":"16","author":"Li","year":"2015","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdrc.21104","article-title":"Diagnosis and management of thrombosis in pregnancy","volume":"105","author":"Konkle","year":"2015","journal-title":"Birth Defects Res. Part. C Embryo Today Rev."},{"key":"ref_76","first-page":"1","article-title":"Regulation of Platelet Activation and Coagulation and Its Role in Vascular Injury and Arterial Thrombosis","volume":"6","author":"Tomaiuolo","year":"2017","journal-title":"Interv. Cardiol. Clin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"Sorensen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_78","first-page":"5026","article-title":"Venous thromboembolism in cancer patients: Still looking for answers","volume":"18","author":"Iorga","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kim, J.S., Kang, E.J., Kim, D.S., Choi, Y.J., Lee, S.Y., Kim, H.J., Seo, H.Y., and Kim, J.S. (2018). Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: A retrospective study. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5154-3"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Chen, J.S., Hung, C.Y., Chang, H., Liu, C.T., Chen, Y.Y., Lu, C.H., Chang, P.H., Hung, Y.S., and Chou, W.C. (2018). Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. Cancers, 10.","DOI":"10.3390\/cancers10120501"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.7150\/jca.26008","article-title":"Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review","volume":"9","author":"Li","year":"2018","journal-title":"J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement","volume":"382","author":"Dangas","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/566\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:02:49Z","timestamp":1760173369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":83,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["cancers12030566"],"URL":"https:\/\/doi.org\/10.3390\/cancers12030566","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,29]]}}}